

Bates College

SCARAB

All Faculty Scholarship

Departments and Programs

2-27-2023

Quantitative analyses of interactions between SpoVG and RNA/ DNA

Timothy C. Saylor
University of Kentucky

Christina R. Savage
University of Kentucky

Andrew C. Krusenstjerna
University of Kentucky

Nerina Jusufovic
University of Kentucky

Wolfram R. Zückert
University of Kansas Medical Center

See next page for additional authors

Follow this and additional works at: https://scarab.bates.edu/faculty_publications

Recommended Citation

Saylor, T. C., Savage, C. R., Krusenstjerna, A. C., Jusufovic, N., Zückert, W. R., Brissette, C. A., Motaleb, M., Schlax, P. J., & Stevenson, B. (2023). Quantitative analyses of interactions between SpoVG and RNA/DNA. *Biochemical and Biophysical Research Communications*, 654, 40-46.

This Article is brought to you for free and open access by the Departments and Programs at SCARAB. It has been accepted for inclusion in All Faculty Scholarship by an authorized administrator of SCARAB. For more information, please contact batesscarab@bates.edu.

Authors

Timothy C. Saylor, Christina R. Savage, Andrew C. Krusenstjerna, Nerina Jusufovic, Wolfram R. Zückert, Catherine A. Brissette, Md Motaleb, Paula Schlax, and Brian Stevenson



Quantitative analyses of interactions between SpoVG and RNA/DNA

Timothy C. Saylor^a, Christina R. Savage^{a,1}, Andrew C. Krusenstjerna^a, Nerina Jusufovic^a, Wolfram R. Zückert^b, Catherine A. Brissette^c, Md Motaleb^d, Paula J. Schlax^e, Brian Stevenson^{a, f, *}

^a Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY, USA

^b Department of Microbiology, Molecular Genetics, and Immunology, University of Kansas Medical Center, Kansas City, KS, USA

^c Department of Biomedical Sciences, University of North Dakota, School of Medicine and Health Sciences, Grand Forks, ND, USA

^d Department of Microbiology and Immunology, East Carolina University, Greenville, NC, USA

^e Department of Chemistry and Biochemistry, Bates College, Lewiston, ME, USA

^f Department of Entomology, University of Kentucky, Lexington, KY, USA



ARTICLE INFO

Article history:

Received 6 February 2023

Accepted 17 February 2023

Available online 27 February 2023

Keywords:

SpoVG

RNA binding protein

DNA binding protein

Borrelia burgdorferi

Electrophoretic mobility shift assay (EMSA)

ABSTRACT

The *Borrelia burgdorferi* SpoVG protein has previously been found to be a DNA- and RNA-binding protein. To aid in the elucidation of ligand motifs, affinities for numerous RNAs, ssDNAs, and dsDNAs were measured and compared. The loci used in the study were *spoVG*, *glpFKD*, *erpAB*, *bb0242*, *flaB*, and *ospAB*, with particular focus on the untranslated 5' portion of the mRNAs. Performing binding and competition assays yielded that the 5' end of *spoVG* mRNA had the highest affinity while the lowest observed affinity was to the 5' end of *flaB* mRNA. Mutagenesis studies of *spoVG* RNA and ssDNA sequences suggested that the formation of SpoVG-nucleic acid complexes are not entirely dependent on either sequence or structure. Additionally, exchanging uracil for thymine in ssDNAs did not affect protein-nucleic acid complex formation.

© 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC license (<http://creativecommons.org/licenses/by-nc/4.0/>).

1. Introduction

SpoVG proteins are conserved across diverse groups of bacteria, including Firmicutes, Spirochaetota, and Myxococcota (Delta-proteobacteria) [1]. The protein's nomenclature derives from early studies of *Bacillus* spp., where it was observed that mutations within the *spoVG* locus impaired sporulation at stage V [2]. The SpoVG homologues of *Borrelia burgdorferi* and other non-sporulating bacterial species affect expression of a broad range of genes, and *spoVG* mutants exhibit physiological defects [3–8]. Our group has studied SpoVG proteins from *B. burgdorferi*, *Staphylococcus aureus*, and *Listeria monocytogenes*, and found that they exhibit affinities for specific DNA sequences [1]. Subsequent studies by Burke and Portnoy found that *L. monocytogenes* SpoVG exhibits a

substantially greater affinity for single-stranded RNAs than for cognate double-stranded DNAs (dsDNAs), and hypothesized that SpoVG functions primarily as an RNA-binding protein [3]. Evaluation of the *B. burgdorferi* homologue found a similarly greater affinity for RNAs [4].

The Lyme disease spirochete, *B. burgdorferi*, is a particularly useful model for studies of gene and protein regulation in a vector-borne pathogen [9–11]. In addition to being the cause of a significant human disease, *B. burgdorferi* infects both vertebrates and ticks [12]. The Lyme spirochete must, therefore, possess mechanisms to accurately determine which host it is in, and produce proteins and other essential factors for each stage of its infectious cycle. *B. burgdorferi* must also recognize when a tick is feeding, in order to undergo the physiological changes that are necessary for transmission into the vertebrate host. Our group's previous data indicate that *B. burgdorferi* SpoVG affects expression levels of numerous proteins and affects bacterial physiology, apparently through its activities as an RNA- and/or DNA-binding protein [4]. To gain further insights into SpoVG function, we identified high- and low-affinity ligands of *B. burgdorferi* SpoVG, which were then employed to gain insights on the ability of SpoVG to bind single-stranded and

* Corresponding author. Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky College of Medicine, Lexington, KY, 40536-0298, USA.

E-mail address: brian.stevenson@uky.edu (B. Stevenson).

¹ Current address: Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA.

double-stranded nucleic acids.

2. Materials and methods

2.1. Purification of recombinant proteins

Polyhistidine-tagged *B. burgdorferi* SpoVG was purified essentially as described previously [1,4]. Briefly, *Escherichia coli* Rosetta II (Invitrogen, MA) was transformed with pBLJ132, which consists of *spoVG* cloned into pET101 [1]. *E. coli* were then grown to an OD₆₀₀ of at least 1.0 in Super Broth (32 g Tryptone, 20 g Yeast Extract, and 5 g NaCl per liter), and recombinant SpoVG expression was induced for 1 h by adding isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. Bacteria were harvested by centrifugation at 5400×g for 30 min and frozen at –80 °C until needed. Resuspended cells were lysed by sonication with the addition of B-PER bacterial protein extraction reagent to 2% v/v (Thermo-Fisher, MA). Recombinant proteins were purified using MagneHis nickel particles (Promega, WI), then dialyzed against EMSA buffer (50 mM Tris-HCl, 25mM KCl, 10% glycerol (v/v), 0.01% Tween 20, 100 nM dithiothreitol (DTT), and 1 mM phenylmethanesulfonyl fluoride (PMSF)). Proteins were concentrated using 10 kDa Amicon centrifugal units (MilliporeSigma, MA) and aliquots were stored at –80 °C until needed. Protein purity and concentration were assessed by SDS-PAGE, Quick Start Bradford protein assay (Bio-Rad), and bicinchoninic acid assay (BCA) (Thermo-Fisher, MA).

2.2. Electromobility shift assay (EMSA)

Fluorescently tagged and untagged DNA and RNA oligonucleotides were synthesized by Integrated DNA Technologies (IDT, IA). The sequences of oligonucleotides used in this study are listed in Table 1 and Supplemental Table 1. DNA and RNA probes were tagged on the 5' end with an IRDye 800 fluorescent tag (LI-Cor, NE) or an Alexa Fluor 488, respectively. Double-stranded DNA (dsDNA) probes and competitors were produced from pairs of separately-synthesized complimentary oligonucleotides by mixing equal molar concentrations, heating to 95 °C, and slowly cooling to room temperature.

EMSAs were performed as previously described [1,4]. Unless stated otherwise, purified proteins were added to 100 nM of labeled nucleic acid probes and incubated at room temperature for 5–15 min. Unlabeled nucleic acid competitors were added prior to the addition of protein. EGTA was added to the indicated reactions to inhibit RNase activity in protein aliquots. Poly-dI-dC was added to indicated gels as a non-specific competitor. One-sixth volume of EMSA loading dye (15 mg/mL Ficol 400, 0.8 mg/mL Orange G) was added. Electrophoresis was performed using pre-run 6% TBE gels (Invitrogen, MA) at 100-V in 0.5x TBE buffer. Gels were imaged and analyzed via densitometry with a ChemiDoc MP and Image-Lab software, respectively (Bio-Rad, CA). Lanes and bands were added manually according to the strongest free probe and the strongest shifted band. Equivalent bands were then added across the entire EMSA. Background noise was calculated and accounted for by the Image-Lab software. Percent shifted was graphed using GraphPad Prism 9 (Dotmatics, MA).

2.3. Calculation of apparent K_D and IC₅₀ values

For direct binding assays, the fraction of bound complex was fit to a one-site saturation ligand binding model (Fraction Bound = B_{max} SpoVG/(K_D + SpoVG)) where B_{max} is the maximum fraction bound and K_D is the apparent dissociation equilibrium constant.

Table 1

5'-3' sequences of dsDNA, ssDNA and RNA used throughout. Red highlighted nucleotides in the ssDNA and RNA sections deviate from the *spoVG* probe. ss22 and ss23 have a deoxyribose backbone with uracil bases instead thymine.

Name	Sequence
dsDNA	
<i>spoVG</i> _{DNA}	AGTTATGTACTTTTTGCGGGAGGCTTATAA
<i>erpAB</i> _{DNA}	CTTATGGAGAAATTTATGAATAAGAAAATGAAA
<i>glpFKD</i> _{DNA}	ATTAATAATAATTTAATAAGGCTTTTATTAGAAAAATTAAT
<i>bb0242</i> _{DNA}	GTATTCAAAAAATAAACTGTCTAAACCTTTTGGAAAAGG
<i>ospAB</i> _{DNA}	GTATTAAGTTATATTAATATAAAAAGGAGAATATATT
<i>flaB</i> _{DNA}	AGGCAAAGGATTTGCCAAAGTCAGAAAT
ssDNA	
<i>spoVG</i> _{CD}	TATGTACTTTTTGCGGGAGGCTTATAA
<i>spoVG</i> _{NC}	TTATAAGCTCCCGCAAAAAGTACATA
ss01	AATGTACTTTTTGCGGGAGGCTTATAA
ss02	GATGTACTTTTTGCGGGAGGCTTATAA
ss03	TATGTACAAAAAGCGGGAGGCTTATAA
ss04	TATGTACCCCCGCGGGAGGCTTATAA
ss05	TATGTACGGGGGCGGGAGGCTTATAA
ss06	TATGTACTTTTTGCGGGTGGCTTATAA
ss07	TATGTACTTTTTGCGGGTCCGAAATAA
ss08	TATGTACTTTTTGCGGGGAATCCATAA
ss09	GTACTTTTTGCGGGAGGCTTATAA
ss10	CTTTTTGCGGGAGGCTTATAA
ss11	TATGTACATTTTTCGCGGGAGGCTTATAA
ss12	TATGTACTTATTGCGGGAGGCTTATAA
ss13	TATGTACTTTTAGCGGGAGGCTTATAA
ss14	TATGTACAATTTGCGGGAGGCTTATAA
ss15	TATGTACTAATTTGCGGGAGGCTTATAA
ss16	TATGTACTTAATGCGGGAGGCTTATAA
ss17	TATGTACTTTAAGCGGGAGGCTTATAA
ss18	TATGTACAAATTTGCGGGAGGCTTATAA
ss19	TATGTACTAAATGCGGGAGGCTTATAA
ss20	TATGTACTTAAAGCGGGAGGCTTATAA
ss21	TATGTACAAAAAGCGGGTCCGAAATAA
ss22	TATGTACUUUUUGCGGGAGGCTTATAA
ss23	UAUGUACUUUUUGCGGGAGGCUUUAUA
RNA	
<i>spoVG</i> _{RNA}	UAUGUACUUUUUGCGGGAGGCUUUAUA
<i>erpAB</i> _{RNA}	AUGGAGAAUUUAUGAAUUAAGAAAUGAAA
<i>glpFKD</i> _{RNA}	AUAUUUUUAUAAGGCUUUUAUAGAAAAUUUAU
<i>bb0242</i> _{RNA}	GUAUUCAAAAAUAACUGUCUAAACUUUUUGAAAAGG
<i>ospAB</i> _{RNA}	GUAUUAAAGUUUAUUUAUUUAUUAAAAGGAGAAUUUAU
<i>flaB</i> _{RNA}	AGGCAAAGGAUUUGCCAAAGUCAGAAUUU
RNA-03	UAUGUACAAAAAGCGGGAGGCUUUAUA
RNA-17	UAUGUACUUUAAGCGGGAGGCUUUAUA
RNA-20	UAUGUACUUUAAGCGGGAGGCUUUAUA

[13]. It should be noted that this estimate of the binding constant is limited by the high concentration of nucleic acid in the binding assays which likely puts acids in the “Titration Regime” but can still be used to determine relative affinities of one sequence to another [13]. In competition assays, data were fit globally to determine the concentration of inhibitor resulting in 50% of the complex being disrupted (IC₅₀) to the equation fraction bound to labeled probe = $m - (m-b)/(1+IC_{50}/[C])$ where m is the maximum signal, b is the minimum (background) signal, [C] is the concentration of the unlabeled nucleic acid competitor, and IC₅₀ is the concentration of the competitor that results in 50% of the complex being disrupted.

3. Results

3.1. *SpoVG* is a site-specific RNA- and DNA-binding protein

We previously reported that *B. burgdorferi* SpoVG can bind to the 5' ends of the borrelial *spoVG* and *glpFKD* mRNAs, and then cognate dsDNAs [4]. It was also found that SpoVG binds within the transcript of a small gene of unknown function, *bb0242*, that is located

between the *glpK* and *glpD* genes [4]. The present studies delved further into the interactions between SpoVG and other nucleic acid sequences to assess relative affinities and mechanisms of binding. Noting that *spoVG* and the *glpFKD* operon are highly expressed during tick colonization but not during mammalian infection, we investigated the ability of SpoVG to bind other borrelial sequences; specifically the 5' ends of *erpAB* (which is repressed during tick colonization but highly expressed during mammalian infection), *ospAB* (which is highly expressed during tick colonization but repressed in mammals), and *flaB* (which is constitutively expressed throughout the borrelial tick-mammal cycle) [4,12,14–18]. Both RNA and dsDNA were examined for each target.

Of the tested probes and competitors, SpoVG exhibited the greatest affinity for the *spoVG* mRNA 5' end, henceforth referred to as *spoVG*_{RNA} (Fig. 1 and Fig. 2). This high affinity binding site was further tested by competition EMSAs using an unlabeled *spoVG*_{RNA} as a competitor (Fig. 1A and Supp. Fig. 1). No intermediate shift was observed indicating that there was no formation of a dsRNA probe. The protein-RNA complex shift stayed above 50% until 1 μ M (10x) of competitor was added. Addition of up to 100 ng/ μ L poly-dI-dC did not result in an appreciable difference of SpoVG binding to the *spoVG*_{RNA} (Fig. 1B), further indicating that binding of SpoVG to *spoVG*_{RNA} is specific. SpoVG also bound to the *glpFKD*_{RNA}, *bb0242*_{RNA}, and *erpAB*_{RNA} probes, but EMSAs did not approach saturation in the tested ranges of SpoVG protein concentrations, indicating that the affinity of SpoVG for those three RNAs is weaker than *spoVG*_{RNA} (Fig. 2).. (Insert Figs. 1 and 2)

Our initial studies of *B. burgdorferi* and *S. aureus* SpoVG found that both proteins preferentially bound to certain dsDNA sequences [1]. In contrast, a study of the *L. monocytogenes* orthologue with a variety of DNA probes led those researchers to conclude that DNA binding appeared to be non-specific [3]. To build upon those observations, we assessed the affinities of *B. burgdorferi* SpoVG for the above-described borrelial sequences as dsDNA. Affinities for all tested dsDNAs were significantly lower than their cognate RNAs

(Fig. 2). The relative affinity of SpoVG to the *spoVG*_{DNA} probe was over 100x weaker than for *spoVG*_{RNA}, with addition of 10 μ M SpoVG protein yielding approximately 30% shifted probe (Fig. 2B). This difference signifies that a substantially higher concentration of SpoVG is required to form a complex with SpoVG_{DNA} dsDNA compared to SpoVG_{RNA}.

These results were highlighted by performing EMSAs of the *spoVG*_{DNA}, *spoVG*_{RNA}, *glpFKD*_{DNA}, and *glpFKD*_{RNA} probes (Supp. Fig. 2). EMSAs with *spoVG* RNA achieved close to 100% shift at 200 nM compared to the unshifted dsDNA at 200 nM concentration (Supp. Fig. 3A). This was also observed with the *glpFKD*_{RNA}. Saturation of the *glpFKD*_{RNA} probe occurred between 1 μ M and 10 μ M SpoVG, whereas the *glpFKD*_{DNA} probe showed almost no detectable shift at that concentration. While SpoVG had an inherently weaker interaction with the DNAs tested than the RNAs, there were still substantial differences when comparing affinities for the DNA probes out of the four tested. SpoVG had the lowest relative affinity for the *erpAB*_{DNA} probe (Fig. 2B and C).

The relative affinities of SpoVG for the *ospAB*_{RNA} and *flaB*_{RNA} were determined by use of unlabeled RNAs as competitors against labeled *spoVG*_{RNA} or *glpFKD*_{RNA} probes. When using the *spoVG*_{RNA} probe, addition of 100x excess of the unlabeled *ospAB*_{RNA} reduced the shifted protein-RNA complex by approximately 18% ($IC_{50} = 5.9 \pm 4.6 \times 10^{-5}$ M), while 100x excess of the unlabeled *flaB*_{RNA} did not detectably affect the SpoVG-*spoVG*_{RNA} complex (Fig. 3A and B). When labeled *glpFKD*_{RNA} was used as a probe, addition of 25x excess of unlabeled *flaB*_{RNA} led to a 20% reduction in the SpoVG-*glpFKD*_{RNA} complex (Fig. 3C). In contrast, 25x excess of unlabeled *glpFKD*_{RNA}, *erpAB*_{RNA}, or *ospAB*_{RNA} reduced binding to the probe by approximately 80%, and unlabeled *spoVG*_{RNA} virtually eliminated the SpoVG-*glpFKD*_{RNA} complex (Fig. 3C). The data above indicate that SpoVG has a substantially greater affinity for RNA compared to DNA, but that this affinity differs based on the sequence of the nucleic acid.




Fig. 1. *spoVG* RNA is a SpoVG high affinity binding site **A.** Competition assay using 100 nM labeled *spoVG*_{RNA}. Free probe is indicated, and the shifted probe is indicated by an asterisk. SpoVG concentration was 500 nM in lanes 2–9. Unlabeled *spoVG*_{RNA} was added at 10 nM, 25 nM, 100 nM, 250 nM, 1 μ M, 2.5 μ M, and 10.0 μ M in lanes 3–9 respectively. EGTA was added to 5 mM. This assay was done in triplicate (Sup. Fig. 1). **B.** Competition assay using labeled *spoVG*_{DNA} and *spoVG*_{RNA} probe against poly-dI-dC. Lanes 1–7 included 100 nM *spoVG*_{DNA} probe. Lanes 8–14 included 100 nM *spoVG*_{RNA} probe. SpoVG was added to lanes 2–7 at 10 μ M and lanes 9–14 at 100 nM. Poly-dI-dC was added in at 1,5,10,50, and 100 ng/ μ L in lanes 3–7 and 10–14 respectively.




Fig. 2. SpoVG has a higher binding affinity for RNA than DNA. A. EMSA using labeled *spoVG*_{RNA}, *erpAB*_{RNA}, *glpFKD*_{RNA}, and *bb0242*_{RNA} at 100 nM from lanes 1–5, 6–10, and 11–15, 16–20 respectively. Free probe is indicated, and the shifted probe is indicated by an asterisk. SpoVG was added to lanes 2–5, 7–10, 12–15, and 17–20 at 50 nM, 100 nM, 200 nM, and 500 nM. B. EMSAs using labeled *spoVG*_{DNA}, *glpFKD*_{DNA}, *erpAB*_{DNA}, and *bb0242*_{DNA} at 100 nM from 1 to 5, 6–10, 11–15, 16–20 respectively. SpoVG was added to lanes 2–5, 7–10, 12–15, and 17–20 at 500 nM, 1 μM, 5 μM, and 10 μM respectively. C. Graph representing the percentage of 100 nM probe shifted due to SpoVG binding from the EMSAs in A and B.

3.2. Effects of nucleic acid sequence on SpoVG-binding

As the SpoVG protein appears to have the strongest affinity for the *spoVG*_{RNA} probe, we made a series of sequence variants to determine whether the sequence or structure of the RNA was important in recognition and affinity of the protein to the nucleic

acid. EMSAs were undertaken using the labeled *spoVG*_{RNA} probe and numerous unlabeled variant nucleic acids as competitors (Table 1). As a cost saving first approach, ssDNA competitors were used for the initial analyses. Sequence variations in competitors included changing the 5' nucleotide, removing 3 or 6 nucleotides from the 5' end, altering the run of five consecutive thymines, and altering an AGGCT sequence near the 3' end (Table 1).

Of the 21 tested unlabeled ssDNAs, only a subset of the oligonucleotides that disrupted the five-thymine run had appreciable impacts on competition for SpoVG (Fig. 4A and B). Competition of the *spoVG*_{RNA} with nucleic acid fragments that replace the sequence TTTT in the unlabeled probe with CCCCC (ss04) or GGGGG (ss05) did not appreciably affect their ability to compete with the wild type *spoVG* sequence (Fig. 4A). However, replacing the run of thymines in the sequence with adenines in some positions: (AAAAA) (ss03), TTATA (ss17), or AAATT (ss18), or with Us (ss21) resulted in reduced competition. Lastly, when combining the changes of the TTTT sequence to AAAAA with deletion of the AGGCT sequence (ss21), the competition was reduced but was similar to that of the AAAAA (ss03) change only.

Based on above results, three unlabeled RNAs were synthesized for use as EMSA competitors: RNA-03 changed the run of five uracils (UUUUU) to adenines (AAAAA), RNA-17 changed the run to UUUAA, and RNA-20 changed it to UUAAA (Table 1). When added to EMSAs at 15-fold excess, each of these mutant competitors was slightly less effective at competing for SpoVG than the *spoVG*_{RNA} sequence (Fig. 4C). RNA-03 saw a 29% decrease in competition, whereas RNA-17 and RNA-20 saw a 7% decrease in competition compared to the wild type sequence. All RNAs effectively competed for SpoVG when added at 50x excess whereas the ssDNA counterparts, ss03 and ss17, were less effective than *spoVG*_{CD} (Table 1 and Fig. Supp. 3A). In contrast, 50x excess of unlabeled *glpFKD*_{RNA} competitor did not compete nearly as well as any tested *spoVG* mutant RNA sequence. (Fig. Supp. 3B). Altogether, this suggests that SpoVG differentially interacts with additional aspects of the *spoVG*_{RNA} that are not present in the *glpFKD*_{RNA}.

Due to the observed differential affinities above between the RNA probes derived from the start of transcription and their cognate dsDNAs, we performed competition assays comparing the coding (*spoVG*_{CD}) and non-coding (*spoVG*_{NC}) strands of DNA. EMSAs were performed in which the two ssDNAs competed against labeled *erpAB*_{RNA}, which was used to inhibit possible base pairing. This competition EMSA indicated that *spoVG*_{NC} better competed against *erpAB*_{RNA} than *spoVG*_{CD} (Supp. Fig. 4A and B). A substantial difference was observed when competitors were added at 100 nM concentration: *spoVG*_{NC} was able to compete away 62% of the SpoVG-*erpAB*_{RNA} complex compared to *spoVG*_{CD}, which only competed away 12%.

3.3. Differences of uracil vs thymine alone can not explain the differences in RNA and ssDNA binding

The differential competition of the SpoVG derived ssDNA and RNA sequences lead us to further investigate whether the presence of uracils in RNA and thymines in ssDNA contributed to differences in SpoVG affinity. To that end, we produced two ssDNAs based on the *spoVG*_{CD} sequence: competitor ss22 replaced only the TTTT with UUUUU, whereas competitor ss23 replaced every thymine in the sequence with uracil (Table 1). Competition analysis using the altered ssDNA sequences did not result in more effective competition than the original SpoVG ssDNA sequence at 5x and 15x competitor concentrations (Fig. 4D).




Fig. 3. SpoVG is a specific RNA binding protein. **A.** Competition assay using 100 nM labeled *spoVG*_{RNA}. Free probe is indicated, and the shifted probe is indicated by an asterisk. The SpoVG concentration was 500 nM in lanes 2–9. Unlabeled *ospAB*_{RNA} was added at 10 nM, 25 nM, 100 nM, 250 nM, 1 μ M, 2.5 μ M, and 10.0 μ M in lanes 3–9 respectively. EGTA was added to 5 mM. **B.** Competition assay using unlabeled *flaB*_{RNA} and 100 nM labeled *spoVG*_{RNA}. Lane values match (A), except unlabeled *flaB*_{RNA} was used instead of *ospAB*_{RNA}. **C.** Competition assay using 100 nM labeled *glpFKD*_{RNA} (lanes 8–14). SpoVG concentration was 500 nM. Competitors were added at a concentration of 2.5 μ M in the following sequence *glpFKD*_{RNA}, *spoVG*_{RNA}, *erpAB*_{RNA}, *bb0242*_{RNA}, and *flaB*_{RNA}. The gamma of entire image was increased to more accurately visualize differences in competition.

4. Discussion

B. burgdorferi SpoVG is a sequence-specific RNA- and DNA-binding protein, exhibiting binding constants of $5.9 \pm 2.1 \times 10^{-8}$ M from direct binding assays and with an apparent IC₅₀ of 1.033×10^{-6} M \pm 2.7×10^{-7} for *spoVG*_{RNA}. Binding affinities for tested dsDNAs appear to be over 100-times weaker than for cognate RNAs, yet selectivity and differential affinity for certain dsDNA sequences was observed.

Analyses with the high-affinity RNA sequence derived from the *spoVG* start of transcription provided insights on the nature of those interactions. This RNA contains a run of five uracils, UUUUU, which, when changed to adenines, AAAAA, substantially affected SpoVG binding. Two additional base replacements, UUUUU to UUUAA or UUUAAA, also led to decreases in SpoVG-RNA complex formation. Note that two other RNAs that SpoVG bound with high affinity also contains runs of uracils: the *glpFKD*_{RNA} probe contains two poly-U tracts, UUUUAAU and UUUUAAU, and the *erpAB*_{RNA} probe contains one poly-U tract, UUUAU. However, *ospAB*_{RNA} contains runs of only two sequential uracils, UU, and the *flaB*_{RNA} contains a single uracil tract of UUU. These results suggest that a poly-U tract may play a role in SpoVG binding. Noting that unlabeled *glpFKD*_{RNA} was less effective than any of the mutated *spoVG* RNAs, it is evident that additional features have important impacts on complex formation.

Having observed that *spoVG* ssDNA and RNA sequence variants showed a wide variation in their abilities to bind SpoVG, we used RNA structure v6.4 to predict the secondary structures of these sequences and the other natural substrates that were observed (Supp. Table 1) [19]. A majority of the constructs that were the least effective competitors e.g. (SS-03 and RNA-03, SS-17 and RNA-17, SS-20 and RNA-20) are predicted to share a secondary structure where the nucleic acid has a stem of 4 or 5 base pairs and a loop with a sequence GGAG. Lacking a 2' hydroxyl group, the RNA sequences may fold into a more A-form helix compared to the same sequence of DNA, providing a possible rationale for why SpoVG prefers RNA over DNA. This seems particularly likely in that replacing thymines

with uracils (ss22 and ss23) was insufficient to increase affinity of the SpoVG protein for these sequences. Yet, sequence ss21, which is predicted to have a different structure, with variations in both the stem and the loop, was still an efficient competitor, suggesting that there are likely other determinants to binding.

The greater affinity of SpoVG for RNA over cognate ssDNA containing uracil implies that SpoVG is more likely to form complexes with RNA rather than DNA either through direct interactions with the backbone or because of RNA's preferred tertiary folds compared to those of DNA. Previous site-directed mutagenesis of SpoVG revealed that two domains are involved with nucleic acid-binding [1]. Residues in the sole alpha helix of the protein confer nucleic acid sequence preference. Two positively charged residues (arginine or lysine) in a separate loop are conserved across all bacterial species and changing either residue to an alanine eliminated nucleic acid binding. Taken together, these results suggest that the charged residues of the loop may bind to the sugar-phosphate backbone and may be better positioned to interact with ribose rather than deoxyribose.

We acknowledge that the sequences used in this study were short fragments of the 5' end of mRNAs and lack the complexity of full-length mRNAs of coding genes. We are presently examining the *B. burgdorferi* transcriptome by RNA immunoprecipitation - sequencing (RIP-Seq) to identify additional high-affinity SpoVG binding sites, which can then be compared to the binding sites herein, to provide an enhanced rational approach to characterizing RNA features that are involved with SpoVG-binding.

In conclusion, the results of these studies indicate that there is definitive preferential affinity of SpoVG for certain RNAs and DNAs within the *B. burgdorferi* genome. Furthermore, SpoVG can bind to numerous sites throughout the transcriptome and genome. *B. burgdorferi* controls levels of SpoVG throughout the infection cycle [4]. Thus, differential expression of SpoVG will result in occupancy of greater or fewer binding sites, facilitating a variety of different phenotypes.




Fig. 4. Mutagenesis of *spoVG* ssDNA and RNA. **A.** EMSA using 100 nM *spoVGRNA* probe and 100 nM of SpoVG in lanes 2–13. ssDNA competitors were added to lanes 3–13 at 5 μ M. Free probe is indicated, and the shifted probe is indicated by an asterisk. Competitors used were *spoVG* + through ss10 (Table 1 and Supp. Table 1). **B.** EMSA using 100 nM *spoVGRNA* probe and 100 nM of SpoVG in lanes 2–15. Competitors at 5 μ M were added to lanes 3–15. Competitors were *spoVGC_{CD}*, ss03, followed by ss11 through ss21 (Table 1). **C.** EMSA using 100 nM *spoVGRNA* probe with 100 nM SpoVG added to lanes 2–6. Unlabeled *spoVGRNA*, RNA-03, RNA-17, and RNA-20 were added at 1.5 μ M to lanes 3–6 respectively. **D.** EMSA using 100 nM of *spoVGRNA* probe and 100 nM of SpoVG added to lanes 2–8. ssDNA competitors consisted of *spoVGC_{CD}*, ss22, and ss23 at 500 nM in lanes 3–5 and 2 μ M in lanes 6–8.

Declaration of competing interest

The authors certify that they do not have any conflicts of interest with this study or report.

Acknowledgments

These studies were funded by US NIH grant R01 AI144126. We thank Tatiana Castro-Padovani and Jessamyn Moore for assistance and helpful comments on this manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bbrc.2023.02.044>.

References

- [1] B.L. Jutras, A.M. Chenail, C.L. Rowland, D. Carroll, M.C. Miller, T. Bykowski, B. Stevenson, Eubacterial SpoVG homologs constitute a new family of site-specific DNA-binding proteins, *PLoS One* 8 (2013), e66683.
- [2] A. Rosenbluh, C.D. Banner, R. Losick, P.C. Fitz-James, Identification of a new developmental locus in *Bacillus subtilis* by construction of a deletion mutation in a cloned gene under sporulation control, *J. Bacteriol.* 148 (1981) 341–351.

- [3] T.P. Burke, D.A. Portnoy, SpoVG is a conserved RNA-binding protein that regulates *Listeria monocytogenes* lysozyme resistance, virulence, and swarming motility, *mBio* 7 (2016), e00240.
- [4] C.R. Savage, B.L. Jutras, A. Bestor, K. Tilly, P.A. Rosa, Y. Tourand, P.E. Stewart, C.A. Brissette, B. Stevenson, *Borrelia burgdorferi* SpoVG DNA- and RNA-binding protein modulates the physiology of the Lyme disease spirochete, *J. Bacteriol.* 200 (2018) e00033, 00018.
- [5] X. Liu, S. Zhang, B. Sun, SpoVG regulates cell wall metabolism and oxacillin resistance in methicillin-resistant *Staphylococcus aureus* strain N315, *Antimicrob. Agents Chemother.* 60 (2016) 3455–3461.
- [6] B. Schulthess, D.A. Bloes, B. Berger-Bächli, Opposing roles of σ_B and σ_B -controlled SpoVG in the global regulation of *esxA* in *Staphylococcus aureus*, *BMC Microbiol.* 24 (2012) 12–17.
- [7] Q. Zhu, B. Liu, B. Sun, SpoVG modulates cell aggregation in *Staphylococcus aureus* by regulating *sasC* expression and extracellular DNA release, *Appl. Environ. Microbiol.* 86 (2020) e00591, 00520.
- [8] Q. Huang, Z. Zhang, Q. Liu, F. Liu, Y. Liu, J. Zhang, G. Wang, SpoVG is an important regulator of sporulation and affects biofilm formation by regulating Spo0A transcription in *Bacillus cereus* 0-9, *BMC Microbiol.* 21 (2021) 172.
- [9] B. Stevenson, J. Seshu, Regulation of gene and protein expression in the Lyme disease spirochete, in: B. Adler (Ed.), *Spirochete Biology: the Post Genomic Era*, Springer-Nature, Heidelberg, 2018, pp. 83–112.
- [10] D.S. Samuels, M.C. Lybecker, X.F. Yang, Z. Ouyang, T.J. Bourret, W.K. Boyle, B. Stevenson, D. Drecktrah, M.J. Caimano, Gene regulation and transcriptomics, in: J.D. Radolf, D.S. Samuels (Eds.), *Lyme Disease and Relapsing Fever Spirochetes*, Caister Academic Press, London, 2021, pp. 87–129.
- [11] B. Stevenson, A.C. Krusenstjerna, T.N. Castro-Padovani, C.R. Savage, B.L. Jutras, T.C. Saylor, The consistent tick-vertebrate infectious cycle of the Lyme disease spirochete enables *Borrelia burgdorferi* to control protein expression by monitoring its physiological status, *J. Bacteriol.* 204 (2022), e0060621.
- [12] J.D. Radolf, M.J. Caimano, B. Stevenson, L.T. Hu, Of ticks, mice, and men: understanding the dual-host lifestyle of Lyme disease spirochaetes, *Nat. Rev. Microbiol.* 10 (2012) 87–98.
- [13] I.A.-O. Jarmoskaite, I. AlSadhan, P.P. Vaidyanathan, D.A.-O. Herschlag, How to measure and evaluate binding affinities, *Elife* (2020) 9. LID - 10.7554/eLife.57264 [doi] LID - e57264.
- [14] J.C. Miller, K. von Lackum, K. Babb, J.D. McAlister, B. Stevenson, Temporal analysis of *Borrelia burgdorferi* Erp protein expression throughout the mammal-tick infectious cycle, *Infect. Immun.* 71 (2003) 6943–6952.
- [15] W.K. Arnold, C.R. Savage, C.A. Brissette, J. Seshu, J. Livny, B. Stevenson, RNA-seq of *Borrelia burgdorferi* in multiple phases of growth reveals insights into the dynamics of gene expression, transcriptome architecture, and noncoding RNAs, *PLoS One* 11 (2016), e0164165, <https://doi.org/10.1371/journal.pone.0164165>.
- [16] U. Pal, X. Yang, M. Chen, L.K. Bockenstedt, J.F. Anderson, R.A. Flavell, M.V. Norgard, E. Fikrig, OspC facilitates *Borrelia burgdorferi* invasion of *Ixodes scapularis* salivary glands, *J. Clin. Investig.* 113 (2004) 220–230, <https://doi.org/10.1172/JCI19894>.
- [17] M. He, Z. Ouyang, B. Troxell, H. Xu, A. Moh, J. Piesman, M.V. Norgard, M. Gomelsky, X.F. Yang, Cyclic di-GMP is essential for the survival of the Lyme disease spirochete in ticks, *PLoS Pathog.* 7 (2011), e1002133, <https://doi.org/10.1371/journal.ppat.1002133>.
- [18] C.J. Pappas, R. Iyer, M.M. Petzke, M.J. Caimano, J.D. Radolf, I. Schwartz, *Borrelia burgdorferi* requires glycerol for maximum fitness during the tick phase of the enzootic cycle, *PLoS Pathog.* 7 (2011), e1002102, <https://doi.org/10.1371/journal.ppat.1002102>.
- [19] J.S. Reuter, D.H. Mathews, RNAstructure: software for RNA secondary structure prediction and analysis, *BMC Bioinf.* 11 (2010) 129, <https://doi.org/10.1186/1471-2105-11-129>.